Health Care M&A plunged over 40% in volume between Q4 2018 and Q1 2019. At $63.5 million, median health care M&A transactions returned to third-highest level.

Pharma and biotech deal volume grew proportionately: close to 30% of all Q1 2019 volume.

Several blockbuster deals, including Shire’s takeover by Takeda Pharmaceuticals, skewed pharma and biotech’s quarterly totals.

Health care services still retained plurality of volume with devices and supplies approaching 20% of Q1 2019 volume.

The median PE deal size—$94.6 billion for median buyouts—remains at historically high levels.

At 42%, PE firms’ portion of M&A remains high even amid downturn.

Health care technology systems clock in at 15% of all PE activity in Q1.